Gene Therapy in Heart Failure  and Cell Regenerative Theory

Barry Greenberg; Joshua Hare

Gene Therapy in Heart Failure  and Cell Regenerative Theory

Moderator:

There is no moderator for this particular article.

Discussants:

There are no discussants for this particular article.

Date: June 15, 2012

Roundtable ID: CV7533

Citation: Med Roundtable Cardiovasc Ed. ; 3(3): 183 - 188.

Summary:
Drs. Barry Greenberg from the University of California - San Diego, San Diego, CA and Joshua Hare from the University of Miami Miller School of Medicine, Miami, FL discussed the topic "Gene Therapy in Heart Failure."

The discussion focused primarily on:

(1) Shifting paradigms for heart failure therapeutics- hemodynamic to neurohormonal

(2) cell regenerative therapy and gene therapy for heart failure

(3) cell therapy versus drug therapy

(4) the use of gene transfer therapy

(5) neurohormonal activation and effective translational research.

(Med Roundtable Cardiovasc Ed. 2012;3(3):183–188) ©2012 FoxP2Media, LLC

Compounds:
No compounds discussed.

Trials:
CUPID, AIRMID, Mesoblast trial

Please register or login to see this content.

Please subscribe to use our print features or to download PDF files.

Open Access Content

Subscribe Now

2014 Physician Survey - Defining an Expert Clinician

Click Here for Results

"This is a growing population and these patients are at risk of going on and developing more symptomatic advanced HF in the future, ... I think there is a substantial need for developing new therapies and new approaches using novel strategies for the management of these patients."
Barry Greenberg, MD

"The cell therapy paradigm is really a major shift, because it’s based on a change in the understanding of the biology of the heart."
Joshua M. Hare, MD

Gene Therapy in Heart Failure and Cell Regenerative Theory

Moderator:

Discussants:

Gene Therapy in Heart Failure  and Cell Regenerative Theory